Dw. Milligan et al., Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT, BR J HAEM, 106(4), 1999, pp. 1020-1026
Between 1978 and 1996 more than 7500 lymphoma transplants have been reporte
d to the European Bone Marrow Transplantation (EBMT) Lymphoma Registry, Thi
s has been examined to establish the incidence of secondary leukaemia and m
yelodysplasia and to relate this to possible prognostic factors, 131 centre
s representing 4998 patients responded to a questionnaire. This identified
66 patients with post transplant myelodysplastic syndrome (MDS)/acute myelo
id leukaemia (AML). The actuarial risk for MDS/AML at 5 years post-transpla
nt (+/-95% CI) was 4.6% (3.1-6.8) for Hodgkin's disease and 3.0% (2.0-4.3)
for non-Hodgkins lymphoma. Multivariate analysis for all patients demonstra
ted an effect of age at transplant, radiotherapy at conditioning, number of
transplants and interval between diagnosis and transplant as risk factors.
For patients with NHL, grade of histology was important (low grade > inter
mediate or high-grade): for Hodgkin's disease, female sex was identified as
a risk factor, These Endings suggest that the incidence of MDS/AML may not
be greater following an autograft than after conventional chemotherapy.